ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Holdings Raised by Sphera Funds Management LTD.

Sphera Funds Management LTD. increased its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 112.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 273,213 shares of the company's stock after purchasing an additional 144,817 shares during the period. Sphera Funds Management LTD. owned approximately 0.39% of ORIC Pharmaceuticals worth $2,205,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Boxer Capital Management LLC purchased a new position in ORIC Pharmaceuticals in the fourth quarter valued at about $13,982,000. Schonfeld Strategic Advisors LLC purchased a new position in ORIC Pharmaceuticals in the fourth quarter valued at about $5,845,000. Balyasny Asset Management L.P. increased its holdings in ORIC Pharmaceuticals by 37.5% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,555,260 shares of the company's stock valued at $12,551,000 after buying an additional 424,194 shares in the last quarter. Diadema Partners LP purchased a new position in ORIC Pharmaceuticals in the fourth quarter valued at about $1,729,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in ORIC Pharmaceuticals by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,295,025 shares of the company's stock valued at $10,452,000 after buying an additional 180,140 shares in the last quarter. 95.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ORIC shares. Oppenheimer dropped their target price on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Wedbush reiterated an "outperform" rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Monday, May 5th. JPMorgan Chase & Co. raised their target price on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $19.17.

ORIC Pharmaceuticals Price Performance

ORIC Pharmaceuticals stock traded up $0.41 during midday trading on Monday, hitting $5.14. 771,399 shares of the stock were exchanged, compared to its average volume of 648,723. ORIC Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.67. The firm has a market cap of $365.39 million, a P/E ratio of -2.82 and a beta of 1.37. The company has a 50 day moving average price of $5.56 and a two-hundred day moving average price of $7.90.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.09. As a group, analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.